Literature DB >> 26070868

Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth.

Feng Yan1,2, Xiaoming Wang2, Lijia Shao2, Mengyuan Ge2, Xiaoya Hu3.   

Abstract

Ubiquitin-like with PHD and ring finger domains 1 (UHRF1), known as ICB90 or Np95, has been found to be overexpressed in numerous cancers. In this study, we evaluated the expression level of UHRF1 in ovarian cancer. UHRF1 levels in paired ovarian cancer tissues and adjacent normal tissues from 80 ovarian cancer patients were detected using relative quantitatively PCR and Western blot. Small interfering RNA (siRNA) was introduced in two human ovarian cancer cell lines (SKOV-3 and OVCAR-3) to downregulate the expression of UHRF1. The proliferation of siRNA-treated cells was examined using cell counting kit-8 (CCK-8) assay. The growth of these cells showed a remarkable decrease. Moreover, flow cytometric and Hoechst 33342 assays were used to detect the apoptosis. The diagnostic value of UHRF1 messenger RNA (mRNA) expression in ovarian cancer was estimated by receiver-operator characteristic (ROC) curve. The correlation between UHRF1 mRNA expression and clinicopathologic features of ovarian cancer patients was evaluated by χ (2) test. Our results demonstrated that both UHRF1 mRNA and protein were highly expressed in ovarian cancer tissues and significantly higher than that in adjacent normal tissues. Moreover, the inhibition of UHRF1 may lead to cells to undergo apoptosis. Thus, UHRF1 could act as a new oncogenic factor in ovarian cancer and be a potential molecular target for ovarian cancer gene therapy.

Entities:  

Keywords:  Cell apoptosis; Ovarian cancer; Small interfering RNA; Tissue; UHRF1

Mesh:

Substances:

Year:  2015        PMID: 26070868     DOI: 10.1007/s13277-015-3638-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression.

Authors:  L Sabatino; A Fucci; M Pancione; V Carafa; A Nebbioso; C Pistore; F Babbio; C Votino; C Laudanna; M Ceccarelli; L Altucci; I M Bonapace; V Colantuoni
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 2.  Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.

Authors:  Mahmoud Alhosin; Tanveer Sharif; Marc Mousli; Nelly Etienne-Selloum; Guy Fuhrmann; Valérie B Schini-Kerth; Christian Bronner
Journal:  J Exp Clin Cancer Res       Date:  2011-04-15

3.  Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth.

Authors:  Feng Yan; Xu-Yan Tan; Yao Geng; Huang-Xian Ju; Yan-Fang Gao; Ming-Chen Zhu
Journal:  Cancer Biother Radiopharm       Date:  2011-04       Impact factor: 3.099

4.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

Review 5.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

Review 8.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

9.  Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma.

Authors:  V Greger; N Debus; D Lohmann; W Höpping; E Passarge; B Horsthemke
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

10.  The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities.

Authors:  Eun-Kyoung Yim Breuer; Mandi M Murph
Journal:  Int J Proteomics       Date:  2011-01-01
View more
  13 in total

1.  Developmental and hormonal regulation of ubiquitin-like with plant homeodomain and really interesting new gene finger domains 1 gene expression in ovarian granulosa and theca cells of cattle.

Authors:  Maria Chiara Perego; Breanne C Morrell; Lingna Zhang; Luis F Schütz; Leon J Spicer
Journal:  J Anim Sci       Date:  2020-07-01       Impact factor: 3.159

2.  UHRF1 epigenetically down-regulates UbcH8 to inhibit apoptosis in cervical cancer cells.

Authors:  Qishu Zhang; Lijun Qiao; Xiao Wang; Changkuan Ding; Jason J Chen
Journal:  Cell Cycle       Date:  2018-01-31       Impact factor: 4.534

3.  UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells.

Authors:  Ting-Ting Ge; Meng Yang; Zhuo Chen; Ge Lou; Tao Gu
Journal:  J Ovarian Res       Date:  2016-07-19       Impact factor: 4.234

4.  Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

5.  The effect of CA125 on metastasis of ovarian cancer: old marker new function.

Authors:  Qin Yuan; Jiayin Song; Weiwei Yang; Hongyan Wang; Qianyu Huo; Jie Yang; Xiaoxu Yu; Yunde Liu; Chen Xu; Huijing Bao
Journal:  Oncotarget       Date:  2017-07-25

6.  CDDO-Me reveals USP7 as a novel target in ovarian cancer cells.

Authors:  Dongjun Qin; Weiwei Wang; Hu Lei; Hao Luo; Haiyan Cai; Caixia Tang; Yunzhao Wu; Yingying Wang; Jin Jin; Weilie Xiao; Tongdan Wang; Chunmin Ma; Hanzhang Xu; Jinfu Zhang; Fenghou Gao; Ying-Li Wu
Journal:  Oncotarget       Date:  2016-11-22

7.  Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma.

Authors:  Xincheng Liu; Huohui Ou; Leyang Xiang; Xianghong Li; Yu Huang; Dinghua Yang
Journal:  Oncotarget       Date:  2017-02-07

8.  Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation.

Authors:  Chuanyuan Wei; Nanhang Lu; Lu Wang; Yong Zhang; Zihao Feng; Yanwen Yang; Fazhi Qi; Jianying Gu
Journal:  Oncol Rep       Date:  2018-04-04       Impact factor: 3.906

Review 9.  The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer.

Authors:  Christian Bronner; Marc Mousli; Waseem Ashraf; Abdulkhaleg Ibrahim; Mahmoud Alhosin; Liliyana Zaayter; Khalid Ouararhni; Christophe Papin; Tanveer Ahmad; Ali Hamiche; Yves Mély
Journal:  Oncotarget       Date:  2017-04-24

Review 10.  Targeting the SET and RING-associated (SRA) domain of ubiquitin-like, PHD and ring finger-containing 1 (UHRF1) for anti-cancer drug development.

Authors:  Debasis Patnaik; Pierre-Olivier Estève; Sriharsa Pradhan
Journal:  Oncotarget       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.